

BT
Amended
SB
CI

2.(amended) The isolated MAGE-A12 HLA class I-binding peptide of claim 1 wherein the isolated peptide ~~comprises~~ an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, fragments thereof comprising SEQ ID NO:6, and functional variants thereof comprising one amino acid addition, substitution or deletion.

3.(amended) The isolated MAGE-A12 HLA class I-binding peptide of claim 1 wherein the isolated peptide ~~consists of~~ an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, fragments thereof comprising SEQ ID NO:6, and functional variants thereof comprising one amino acid addition, substitution or deletion.

4.(amended) An isolated MAGE-A12 HLA class Ibinding peptide comprising a fragment of the amino acid sequence of SEQ ID NO:2 which binds HLA Cw*07, or a functional variant thereof comprising one amino acid addition, substitution or deletion, wherein the functional variant binds HLA Cw*07.

Remarks

Applicants have amended the claims to clarify the claim language. No new matter has been added.

Restriction Requirement

Applicants affirm the election of Group I, claims 1-4, 7, 8, 42 and 43, and the election of the species, SEQ ID NO:6. Applicants also understand that the Examiner has included SEQ ID NO:5 in the prior art searching.

Rejections Under 35 U.S.C. 112, First Paragraph

The Examiner rejected claims 1-4, 7, 8, 42 and 43 as not having an adequate written description in the specification. Applicants have made amendments to the claims to address certain aspects of the rejection and otherwise respectfully traverse the rejection.